Bedaquiline for the treatment of drug-resistant tuberculosis

References

• Belard S, Janssen S, Osbak KK, et al. Limited access to drugs for resistant tuberculosis: a call to action. J Public Health (Oxf) 2014. [Epub ahead of print]
   Google Scholar
• WHO. Global tuberculosis report 2014. Available from: http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1 [Last accessed on 18 January 2015]
   Google Scholar
• Calligaro GL, Moodley L, Symons G, et al. The medical and surgical treatment of drug-resistant tuberculosis. J Thorac Dis 2014;6(3):186-95
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Mauch V, Migliori GB, et al. Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient’s economic disaster. Eur Respir J 2014;43(6):1563-6
   PubMed Web of Science ®Google Scholar
• Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012;40(1):143-51
   PubMedGoogle Scholar
• Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013;42(1):169-79
   PubMed Web of Science ®Google Scholar
• Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013;42(1):156-68
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J 2015;45(1):25-9
   PubMed Web of Science ®Google Scholar
• Garcia-Prats AJ, Rose PC, Hesseling AC, et al. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations. Tuberculosis (Edinb) 2014;94(2):93-104
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012;40(6):1430-42
   PubMed Web of Science ®Google Scholar
• Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014;371(17):1599-608
   PubMed Web of Science ®Google Scholar
• Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014;371(17):1588-98
   PubMed Web of Science ®Google Scholar
• Blair HA, Scott LJ. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs 2015;75(1):91-100
   PubMedGoogle Scholar
• Sotgiu G, Pontali E, Centis R, et al. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev Anti Infect Ther 2015;13(3):305-15
   PubMed Web of Science ®Google Scholar
• Johnson & Johnson. SIRTURO® (bedaquiline) receives conditional approval in the European Union for the treatment of multi-drug resistant tuberculosis. Available from: www.investor.jnj.com/releasedetail.cfm?ReleaseID=831021 [Last accessed on 28 April 2014]
   Google Scholar
• Lakshmanan M, Xavier AS. Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis. J Young Pharm 2013;5(4):112-15
   PubMedGoogle Scholar
• Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 2014;14(4):327-40
   PubMed Web of Science ®Google Scholar
• Chahine EB, Karaoui LR, Mansour H. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother 2014;48(1):107-15
   PubMed Web of Science ®Google Scholar
• Leibert E, Danckers M, Rom WN. New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline. Ther Clin Risk Manag 2014;10:597-602
   PubMed Web of Science ®Google Scholar
• Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007;3(6):323-4
   PubMed Web of Science ®Google Scholar
• Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009;53(3):1290-2
   PubMed Web of Science ®Google Scholar
• Andries K, Gevers T, Lounis N. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob Agents Chemother 2010;54(11):4540-4
   PubMed Web of Science ®Google Scholar
• Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007;51(3):1011-15
   PubMed Web of Science ®Google Scholar
• Lounis N, Veziris N, Chauffour A, et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006;50(11):3543-7
   PubMed Web of Science ®Google Scholar
• Lounis N, Gevers T, Van Den Berg J, et al. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother 2008;52:3568-72
   PubMed Web of Science ®Google Scholar
• Lanoix JP, Betoudji F, Nuermberger E. Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2014;58(4):2316-21
   PubMedGoogle Scholar
• Veziris N, Ibrahim M, Lounis N, et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med 2009;179(1):75-9
   PubMed Web of Science ®Google Scholar
• Dhillon J, Andries K, Phillips PP, et al. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis (Edinb) 2010;90(5):301-5
   PubMed Web of Science ®Google Scholar
• Wallis RS, Jakubiec W, Mitton-Fry M, et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One 2012;7(1):e30479
   PubMed Web of Science ®Google Scholar
• Rouan MC, Lounis N, Gevers T, et al. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 2012;56(3):1444-51
   PubMed Web of Science ®Google Scholar
• Ibrahim M, Truffot-Pernot C, Andries K, et al. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 2009;180(6):553-7
   PubMed Web of Science ®Google Scholar
• Tasneen R, Li SY, Peloquin CA, et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011;55(12):5485-92
   PubMed Web of Science ®Google Scholar
• Veziris N, Ibrahim M, Lounis N, et al. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One 2011;6(3):e17556
   PubMed Web of Science ®Google Scholar
• Zhang T, Li SY, Williams KN, et al. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 2011;184(6):732-7
   PubMed Web of Science ®Google Scholar
• Svensson EM, Murray S, Karlsson MO, et al. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Winter H, Egizi E, Murray S, et al. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects. Antimicrob Agents Chemother 2015;59(2):1219-24
   PubMed Web of Science ®Google Scholar
• Huitric E, Verhasselt P, Koul A, et al. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2010;54(3):1022-8
   PubMed Web of Science ®Google Scholar
• Petrella S, Cambau E, Chauffour A, et al. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother 2006;50(8):2853-6
   PubMed Web of Science ®Google Scholar
• Huitric E, Verhasselt P, Andries K, et al. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007;51(11):4202-4
   PubMed Web of Science ®Google Scholar
• Matteelli A, Carvalho AC, Dooley KE, et al. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 2010;5(6):849-58
   PubMed Web of Science ®Google Scholar
• Chan B, Khadem TM, Brown J. A review of tuberculosis: focus on bedaquiline. Am J Health Syst Pharm 2013;70(22):1984-94
   PubMed Web of Science ®Google Scholar
• Dooley KE, Park JG, Swindells S, et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr 2012;59(5):455-62
   PubMed Web of Science ®Google Scholar
• Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother 2014;58(11):6406-12
   PubMed Web of Science ®Google Scholar
• Sirturo, Sirturo full prescribing information. 2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf
   Google Scholar
• Haxaire M. Phase 2 open-label trial of TMC207 in an MDR-TB treatment regimen. In: 42nd Union World Conference on Lung Health, Lille, France; 2011
   Google Scholar
• Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52(8):2831-5
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012;380(9846):986-93
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 2013;57(5):2199-203
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360(23):2397-405
   PubMed Web of Science ®Google Scholar
• Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012;56(6):3271-6
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014;371(8):723-32
   PubMed Web of Science ®Google Scholar
• Visser BJ, van Vugt M, Grobusch MP. Malaria: an update on current chemotherapy. Expert Opin Pharmacother 2014;15(15):2219-54
   PubMed Web of Science ®Google Scholar
• FDA; Highlights of prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf [Last accessed on 18 January 2015]
   Google Scholar
• Nunn AJ, Rusen ID, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 2014;15:353
   PubMed Web of Science ®Google Scholar
• Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182(5):684-92
   PubMed Web of Science ®Google Scholar
• Resist-tb. DR-TB clinical trial progress report. Available from: www.resisttb.org/ [Last accessed on 18 January 2015]
   Google Scholar
• Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet):2014;383(9928):1572-9
   Google Scholar
• Zignol M, Sismanidis C, Falzon D, et al. Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J 2013;42(3):701-7
   PubMed Web of Science ®Google Scholar
• Schaaf HS, Garcia-Prats AJ, Hesseling AC, et al. Managing multidrug-resistant tuberculosis in children: review of recent developments. Curr Opin Infect Dis 2014;27(3):211-19
   PubMedGoogle Scholar
• Poorana Ganga Devi NP, Swaminathan S. Drug-resistant tuberculosis: pediatric guidelines. Curr Infect Dis Rep 2013;15(5):356-63
   PubMedGoogle Scholar
• Thee S, Detjen A, Wahn U, et al. Pyrazinamide serum levels in childhood tuberculosis. Int J Tuberc Lung Dis 2008;12(9):1099-101
   PubMedGoogle Scholar
• Thee S, Detjen A, Wahn U, et al. Rifampicin serum levels in childhood tuberculosis. Int J Tuberc Lung Dis 2009;13(9):1106-11
   PubMedGoogle Scholar
• Thee S, Garcia-Prats AJ, McIlleron HM, et al. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children. Antimicrob Agents Chemother 2014;58(5):2948-51
   Google Scholar
• Thee S, Garcia-Prats AJ, Draper HR, et al. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Clin Infect Dis 2015;60(4):549-56
   Google Scholar
• CDC. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR 2013;62(9
   Google Scholar
• IMPAACT. IMPAACT Studies in Development. http://impaactnetwork.org/studies/developing.asp [Last accessed on 23 April 2014]
   Google Scholar
• WHO. Interim guidance. Available from: www.who.int/mediacentre/news/notes/2013/bedaquiline_mdr_tb_20130613/en/ [Last accessed on 15 January 2015]
   Google Scholar
• CDC. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep 2013;62(RR-09):1-12
   Google Scholar
• Migliori GB, Lienhardt C, Weyer K, et al. Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. Eur Respir J 2014;44(6):1412-17
   PubMed Web of Science ®Google Scholar
• WHO. Policy implementation package for new TB drug introduction. Available from: www.who.int/tb/PIPnewTBdrugs.pdf [Last accessed on 09 February 2015]
   Google Scholar
• Blasi F, Dara M, van der Werf MJ, et al. Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. Eur Respir J 2013;41(3):491-4
   PubMedGoogle Scholar
• D’Ambrosio L, Tadolini M, Dupasquier S, et al. ERS/WHO tuberculosis consilium: reporting of the initial 10 cases. Eur Respir J 2014;43(1):286-9
   PubMedGoogle Scholar
• Horsburgh CRJr, Haxaire-Theeuwes M, Lienhardt C, et al. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013;17(2):146-52
   PubMedGoogle Scholar
• Conradie F, Meintjes G, Hughes J, et al. Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis. S Afr Med J 2014;104(3):164-6
   PubMedGoogle Scholar
• STOP-TB-Partbership. Global drug facility. Availablr from http://stoptb.org/gdf/ [Last accessed on 15 Janurary 2015]
   Google Scholar
• WHO. Cost-effectiveness of introducing bedaquiline in MDR-TB regimens - a explanatory analysis. Available from: www.who.int/tb/challenges/mdr/CEA_bdqreport_final.pdf?ua=1 [Last accessed on 15 January 2015]
   Google Scholar
• WHO. The use of bedaquiline in the treatment of multi-drug resistant tuberculosis. Available from: www.who.int/tb/challenges/mdr/Report_EGM_BDQ_2013.pdf?ua=1 [Last accessed on 15 January 2015]
   Google Scholar
• Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014;43(1):289-92
   PubMed Web of Science ®Google Scholar
• van Halsema C, Humphreys S, Bonington A. Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient. Eur Respir J 2014;43(1):292-4
   PubMed Web of Science ®Google Scholar
• Danckers M, Lesko MB, Adamson R, et al. Compassionate use of bedaquiline in the treatment of pulmonary XDR-TB. Int J Tuberc Lung Dis 2014;18(12):1522-5
   PubMed Web of Science ®Google Scholar
• Udwadia ZF, Amale RA, Mullerpattan JB. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India. Int J Tuberc Lung Dis 2014;18(11):1315-18
   PubMed Web of Science ®Google Scholar
• Guglielmetti L, Le Du D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2014;60(2):188-94
   PubMedGoogle Scholar
• Somoskovi A, Bruderer V, Homke R, et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 2015;45(2):554-7
   PubMed Web of Science ®Google Scholar
• Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014;58(5):2979-81
   PubMed Web of Science ®Google Scholar
• Andries K, Villellas C, Coeck N, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014;9(7):e102135
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00910871?term=bedaquiline&phase=1&rank=1&sect=X4301256#othr [Last accessed on 12 January 2015]
   Google Scholar
• Koul A, Vranckx L, Dhar N, et al. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun 2014;5:3369
   PubMed Web of Science ®Google Scholar
• Reddy VM, Einck L, Andries K, et al. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 2010;54(7):2840-6
   PubMed Web of Science ®Google Scholar
• Shang S, Shanley CA, Caraway ML, et al. Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob Agents Chemother 2011;55(1):124-31
   PubMedGoogle Scholar
• Williams K, Minkowski A, Amoabeng O, et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012;56(6):3114-20
   PubMed Web of Science ®Google Scholar
• TMC207-TiDP13-C110: interaction Study With Lopinavir/Ritonavir in Healthy Volunteer. Available from: https://clinicaltrials.gov/ct2/show/NCT00828529
   Google Scholar
• TMC207-TiDP13-C117: interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP). Available from: https://clinicaltrials.gov/ct2/show/NCT00910806
   Google Scholar
• Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers. Available from: https://clinicaltrials.gov/ct2/show/NCT00992069
   Google Scholar
• A Study of TMC207 in patients with moderately impaired hepatic function. Available from: https://clinicaltrials.gov/ct2/show/NCT01012284
   Google Scholar
• TMC207TBC1003 - A study in healthy volunteers investigating the effect of single-dose TMC207 on the QT/QTc Interval Under Fed Conditions. Available from: https://clinicaltrials.gov/ct2/show/NCT01291563
   Google Scholar
• A study to determine the relative oral bioavailability of single dose administration of TMC207, under fed and fasted conditions in healthy participants. Available from: https://clinicaltrials.gov/ct2/show/NCT00946842
   Google Scholar
• TMC207 +/- Rifabutin/Rifampin. Available from: https://clinicaltrials.gov/ct2/show/NCT01341184
   Google Scholar
• A study to assess the relative bioavailability of TMC207 following single-dose administrations of two pediatric formulations in healthy adult participants. Available from: https://clinicaltrials.gov/ct2/show/NCT01803373
   Google Scholar
• PK interaction between rifapentine or rifampicin and a single dose of TMC207 in Healthy Subjects (TMC207-CL002). Available from: https://clinicaltrials.gov/ct2/show/NCT02216331
   Google Scholar
• TMC207-C202: study to evaluate bactericidal activity of multiple oral doses of TMC207 in subjects with sputum-smear positive tuberculosis. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00523926
   Google Scholar
• Evaluation of early bactericidal activity in pulmonary tuberculosis with(J-M-Pa-Z). Available from: https://clinicaltrials.gov/ct2/show/NCT01215851
   Google Scholar
• Evaluation of early bactericidal activity in pulmonary tuberculosis. Available from: https://clinicaltrials.gov/ct2/show/NCT01215110
   Google Scholar
• Evaluation of early bactericidal activity in pulmonary tuberculosis with clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) (NC-003). Available from: https://clinicaltrials.gov/ct2/show/NCT01691534
   Google Scholar
• TMC207-TiDP13-C208: anti-bacterial activity, safety, and tolerability of TMC207 in participants with multi-drug resistant mycobacterium tuberculosis (MDR-TB). Available from: https://clinicaltrials.gov/ct2/show/NCT00449644
   Google Scholar
• A Phase 2 Open label partially randomized trial to evaluate the efficacy, safety and tolerability of combinations of bedaquiline, moxifloxacin, PA-824 and pyrazinamide in adult subjects with drug-sensitive or multi drug-resistant pulmonary tuberculosis. (NC-005). Available from: https://clinicaltrials.gov/ct2/show/NCT02193776
   Google Scholar